Advertisement

Assay of ß-Glucosidase and Sphingomyelinase for Identification of Patients and Carriers of Gaucher’s and Niemann-Pick Diseases

  • David A. Wenger
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 101)

Abstract

Since the middle 1960’s the enzymatic defects in Gaucher and Niemann-Pick diseases have been recognized (1,2). Both autosomal recessive diseases are caused by a deficiency of a lysosomal enzyme required for the degradation of normal cell components. Gaucher disease presents clinically in at least three sub-types: adult form (non-neuropathic or Type 1), infantile form (acute neuropathic or Type 2) and juvenile form (subacute neuropathic or Type 3). Although the patients are quite different in clinical picture all appear to have a deficiency of glucosylceramide ß-glucosidase activity in all tissues tested. Early studies on easily obtained tissues such as leukocytes and cultured skin fibroblasts demonstrated that diagnosis of affected patients was possible without the need for organ biopsy (3). Although much of the earliest research on the enzyme defect was done using radioactively labeled glucosylceramide, additional studies demonstrated that the synthetic ß-glucoside, 4-methylumbelliferyl-ß-D-glucoside,could be used for diagnosis and identification of carriers in easily obtained tissue samples (4,5). Through a measurement of the ability of a tissue sample to hydrolyze this synthetic derivative, a measure of the ability to hydrolyze the natural substrate should be interpreted. Although these methods are workable in some laboratories frequently problems arose in the interpretation of the values. Due to the limited number of laboratories having the natural substrate suitably labeled, it would be preferable to use the commercially available synthetic substrate, if a reliable method were developed. It is known that bile salt detergents are required in the in vitro assay for hydrolysis of some natural sphingolipids.

Keywords

Gauche Disease Synthetic Substrate Sodium Taurocholate Culture Skin Fibroblast Sphingomyelinase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brady, R.O., Kanfer, J.N. and Shapiro, D.: Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem. Biophys. Res. Commun. 18: 221–225 (1965).PubMedCrossRefGoogle Scholar
  2. 2.
    Brady, R.O., Kanfer, J.N., Mock, M.B. and Fredrickson, D.S.: The metabolism of sphingomyelin, II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc. Nat. Acad. Sci. U.S.A. 55: 366–369 (1966).CrossRefGoogle Scholar
  3. 3.
    Kampine, J.P., Brady, R.O., Kanfer, J.N., Feld, M. and Shaprio, D.: Diagnosis of Gaucher’s disease and Niemann-Pick disease with small samples of venous blood. Science 155: 86–88 (1966).CrossRefGoogle Scholar
  4. 4.
    Beutler, E. and Kuhl, W.: The diagnosis of the adult type of Gaucher’s disease and its carrier state by demonstration of deficiency of 8-glucosidase activity in peripheral blood leukocytes. J. Lab. Clin. Med. 76: 747–755 (1970).PubMedGoogle Scholar
  5. 5.
    Ho, M.W., Seck, J., Schmidt, D., Veath, M.L., Johnson, W., Brady, R.O. and O’Brien, J.S.: Adult Gaucher’s disease: Kindred studies and demonstration of a deficiency of acid 8-glucosidase in cultured fibroblasts. Amer. J. Hum. Genet. 24: 37–45 (1972).PubMedGoogle Scholar
  6. 6.
    Gatt, S.: Magnesium-dependent sphingomyelinase. Biochem. Biophys. Res. Commun. 68: 235–241 (1976).PubMedCrossRefGoogle Scholar
  7. 7.
    Rao, B.G. and Spence, M.W.: Sphingomyelinase activity at pH 7.4 in human brain and comparison to activity at pH 5.0. J. Lipid Res. 17: 506–515 (1976).PubMedGoogle Scholar
  8. 8.
    Stoffyn, P., Stoffyn, A. and Hauser, G.: Structure of sulfa-tides biosynthesized in vitro. J. Lipid Res. 12: 318–323 (1971).PubMedGoogle Scholar
  9. 9.
    Stoffel, W., LeKim, D. and Tschung, T.S.: A simple chemical method for labeling phosphatidylcholine and sphingomyelin in the choline moiety. Hoppe-Seyler’s Z. Physiol. Chem. 352: 1058–1064 (1971).CrossRefGoogle Scholar
  10. 10.
    Wenger, D.A., Sattler, M., Clark, C. and Wharton, C.: I-Cell disease: Activities of lysosomal enzymes toward natural and synthetic substrates. Life Sci. 19: 413–420 (1976).PubMedCrossRefGoogle Scholar
  11. 11.
    Wenger, D.A., Sattler, M. and Markey, S.P.: Deficiency of monogalactosyl diglyceride ß-galactosidase activity in Krabbe disease. Biochem. Biophys. Res. Commun. 53: 680–685 (1973).PubMedCrossRefGoogle Scholar
  12. 12.
    Wenger, D.A., Barth, G. and Githens, J.H.: Nine cases of sphingomyelin lipidosis. A new variant in Spanish-American children. Amer. J. Dis. Child, in press.Google Scholar
  13. 13.
    Grover, W.D. and Naiman, J.L.: Progressive paresis of vertical gaze in lipid storage disease. Neurology 21: 896–899 (1971).PubMedCrossRefGoogle Scholar
  14. 14.
    Dunn, H.C. and Sweeney, V.P.: Progressive supranuclear palsy in an unusual juvenile variant of Niemann-Pick disease. Neurology 21: 442 (1971).Google Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • David A. Wenger
    • 1
  1. 1.Department of PediatricsUniversity of Colorado Medical CenterDenverUSA

Personalised recommendations